BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 29938199)

  • 1. Hypoxia-Inducible Factor 2-Dependent Pathways Driving Von Hippel-Lindau-Deficient Renal Cancer.
    Meléndez-Rodríguez F; Roche O; Sanchez-Prieto R; Aragones J
    Front Oncol; 2018; 8():214. PubMed ID: 29938199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
    Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
    Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formation of Renal Cysts and Tumors in Vhl/Trp53-Deficient Mice Requires HIF1α and HIF2α.
    Schönenberger D; Harlander S; Rajski M; Jacobs RA; Lundby AK; Adlesic M; Hejhal T; Wild PJ; Lundby C; Frew IJ
    Cancer Res; 2016 Apr; 76(7):2025-36. PubMed ID: 26759234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity.
    Mathew LK; Lee SS; Skuli N; Rao S; Keith B; Nathanson KL; Lal P; Simon MC
    Cancer Discov; 2014 Jan; 4(1):53-60. PubMed ID: 24189146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD70-Targeted Micelles Enhance HIF2α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells.
    Trac N; Oh HS; Jones LI; Caliliw R; Ohtake S; Shuch B; Chung EJ
    Molecules; 2022 Dec; 27(23):. PubMed ID: 36500549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
    Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU
    Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of radiation and ibuprofen on normoxic renal carcinoma cells overexpressing hypoxia-inducible factors by loss of von Hippel-Lindau tumor suppressor gene function.
    Palayoor ST; Burgos MA; Shoaibi A; Tofilon PJ; Coleman CN
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4158-64. PubMed ID: 15217953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuberous sclerosis complex protein 1 expression is affected by VHL Gene alterations and HIF-1α production in sporadic clear-cell renal cell carcinoma.
    Damjanovic SS; Ilic BB; Beleslin Cokic BB; Antic JA; Bankovic JZ; Milicevic IT; Rodic GS; Ilic DS; Todorovic VN; Puskas N; Tulic CD
    Exp Mol Pathol; 2016 Dec; 101(3):323-331. PubMed ID: 27845047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma.
    Luu VD; Boysen G; Struckmann K; Casagrande S; von Teichman A; Wild PJ; Sulser T; Schraml P; Moch H
    Clin Cancer Res; 2009 May; 15(10):3297-304. PubMed ID: 19401348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.
    Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV
    Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIF alpha expression in VHL-deficient renal cancer cells is dependent on phospholipase D.
    Toschi A; Edelstein J; Rockwell P; Ohh M; Foster DA
    Oncogene; 2008 Apr; 27(19):2746-53. PubMed ID: 17998935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2α.
    Fan Y; Li H; Ma X; Gao Y; Bao X; Du Q; Ma M; Liu K; Yao Y; Huang Q; Zhang Y; Zhang X
    Oncotarget; 2016 Apr; 7(14):18280-94. PubMed ID: 26943772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of HIF1α in renal cell carcinoma tumorigenesis.
    Gudas LJ; Fu L; Minton DR; Mongan NP; Nanus DM
    J Mol Med (Berl); 2014 Aug; 92(8):825-36. PubMed ID: 24916472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas.
    Toledo RA
    Endocr Relat Cancer; 2017 Sep; 24(9):C9-C19. PubMed ID: 28667082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
    Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Association Between Ascorbate and the Hypoxia-Inducible Factors in Human Renal Cell Carcinoma Requires a Functional Von Hippel-Lindau Protein.
    Wohlrab C; Vissers MCM; Phillips E; Morrin H; Robinson BA; Dachs GU
    Front Oncol; 2018; 8():574. PubMed ID: 30555801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VHL and Hypoxia Signaling: Beyond HIF in Cancer.
    Zhang J; Zhang Q
    Biomedicines; 2018 Mar; 6(1):. PubMed ID: 29562667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
    Maynard MA; Ohh M
    Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas.
    Cuevas Y; Hernández-Alcoceba R; Aragones J; Naranjo-Suárez S; Castellanos MC; Esteban MA; Martín-Puig S; Landazuri MO; del Peso L
    Cancer Res; 2003 Oct; 63(20):6877-84. PubMed ID: 14583486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.